Reply To: Traders Market Weekly: Embrace the Chaos in 2023

#49643
Truman
Participant

Friday – December 23

All day – The FDA action date on Coherus BioSciences’ (CHRS) toripalimab arrives. Phase 2 interim analysis released previously noted encouraging clinical activity with no specific data. The stock has rallied in the past off toripalimab developments.

All day – Mullen Automotive (MULN) shareholders will vote on the proposed increase in the aggregate number of authorized shares of common stock to 5B from 1.75B. Mullen is also asking shareholders to approve an up to 1-for-25 reverse stock split and an amendment to facilitate the issuance of $150B in convertible notes and up to $190Min convertible preferred stock.

All day – Shareholders with Viveon Health Acquisition (VHAQ) will meet to vote on taking aesthetics company Suneva public in a SPAC deal.

8:30 a.m. The durable goods order release for November is expected to show a 0.8% decline compared to the 1.1% gain in October. A decrease in aircraft orders from Boeing (BA) is expected to be a factor.